Posaconazole is indicated for prophylaxis and treatment of invasive aspergillosis. 
| INTRODUC TI ON
Invasive fungal infections (IFIs) are still the most common infectionrelated causes for death among immunocompromised patients 1, 2 . Posaconazole is active against a wide spectrum of pathogens in-
Haematopoietic stem cell transplant recipients (HSCT)
cluding Candida species, Aspergillus species and zygomycetes 5 . This has led to posaconazole being used for prophylaxis and treatment of fungal infections [6] [7] [8] . However, posaconazole plasma concentrations may be influenced by other medications and diet, especially when posaconazole suspension is used [9] [10] [11] [12] . Additionally, related to the clinical condition of the patient, the physiological status of these patients can have an impact on pharmacokinetics of different drugs. For instance, there can be a change in the volume of distribution during fluid therapy and metabolism or clearance of drugs during hepatic and renal function disorders 13 . A significant variation of posaconazole concentrations has been reported between and within patients 9, 10 .
Therapeutic drug monitoring (TDM) is recommended in guide-
lines for treatment optimisation for posaconazole and other azoles like voriconazole and itraconazole 2, 3 . TDM can be recommended based on an exposure-response relationship 14 and association of higher drug concentrations with better outcome in daily practice 6, 7, 15 . For posaconazole, there is considered to be clinical benefit from TDM as posaconazole concentrations show large inter-and intra-patient variability, especially when the suspension is used 9, 16, 17 .
In contrast to the suspension, currently used posaconazole tablets and intravenous infusion are expected to result in more stable posaconazole concentrations 18, 19 . TDM of posaconazole has been performed for several years [20] [21] [22] [23] , but the quality of TDM (application to clinical practice, dose alteration recommendations by pharmacists, optimal timing of measurements) and its implication to clinical practice has not been extensively addressed in studies as it has been for voriconazole 24 . Also, there is minimal information available on the potential benefit of TDM in clinical practice for the newer drug formulations. Therefore, TDM of posaconazole has continued to be a subject of debate 25, 26 . A recent study investigated the effect of inflammation reflected by C-reactive protein (CRP) on posaconazole metabolism
27
. It was concluded that CRP does not affect posaconazole exposure. However, other laboratory markers may be associated with altered drug exposure. For instance, due to chemotherapy, concomitant medications can cause liver function disorders which affect the pharmacokinetic processes like absorption, distribution, elimination, metabolism, which can lead to changes in posaconazole exposure 28 . Analysing potential effect of routine laboratory markers can help defining the appropriate population for TDM of posaconazole.
The aim of this study was to evaluate the TDM practice in hae- 
| MATERIAL AND ME THODS
A post hoc analysis was performed from a prospective observational study conducted between August 2015 and June 2017 in the University Medical Center Groningen (UMCG), the Netherlands and prophylaxis); however, no upper toxicity threshold for posaconazole levels is known 15, 30 . For this study, steady state was assumed on day 6 with a loading dose and on day 10 without a loading dose 31 .
The concentrations obtained prior to steady state were not included in the longitudinal analysis. The samples that were not at steady state were used to analyse TDM practices of our hospital.
The recommendations including dosage advice given by the clinical pharmacist if the posaconazole concentrations were out of the therapeutic range were collected from the electronic prescribing and laboratory information systems. To determine intra-patient variability in posaconazole plasma concentrations, patients who had more than one trough concentration measured were included in this subgroup analysis.
For the analysis of TDM practices, it was documented if a recommendation was provided when posaconazole concentrations were out of the therapeutic window. Additionally, the overall number of recommendations provided and how many of these required a dosage change were summarised. When a recommendation to change the dose was followed by an actual dose change, this was considered as a successful implementation into patient care.
For patients who received posaconazole for prophylaxis, occurrence of a breakthrough invasive fungal infection was documented.
For all patients (receiving posaconazole for prophylaxis and treatment), 28-day and 12-week overall survival was documented, to analyse short-and long-term survival. It was taken into account that optimum IFI treatment duration is 6-12 weeks. Multiple imputation, using predictive mean matching on all variables in the mixed model and 20 imputation data sets, was applied as sensitivity analysis. Pooled estimates were obtained using Rubin's rule.
The analyses were conducted with SAS version 9.4.
| RE SULTS

| Patient characteristics
Between August 2015 and June 2017, 47 patients with a median age of 62 (IQR 56-67) were enrolled in this study and 217 posaconazole samples were available for analysis for TDM practices and 182 samples for longitudinal analysis. Seven samples were excluded for further analysis as posaconazole was not detectable (<0.1 mg/L) because the drug was stopped before that time, and one sample for one patient because of missing start date.
Most common underlying disease was acute myeloid leukaemia (AML, 61%), and the majority of patients (70%) received posaconazole for prophylaxis. Posaconazole modified release (MR) tablets were the main drug formulation used (89%), and five patients (11%)
had treatment with both intravenous infusion which was followed by MR tablet throughout the study. Almost half (49%; 23/47) of the patients received a loading dose of 300 mg two times daily on the first day of treatment. The median daily dose for all measured concentrations was 4.1 mg/kg (IQR 3.5-6.1), two patients were on dose 200 mg/day (prophylaxis), 33 patients were on dose 300 mg/day (26 prophylaxis, seven treatment), one patient was on dose 600 mg/day (treatment) and for 11 patients (four prophylaxis, seven treatment) the doses varied throughout treatment period. Other patient characteristics are described in Table 1 . Figure 1 shows first and subsequent posaconazole concentrations. 
| Analysis of TDM practices
| Prophylaxis with posaconazole
Thirty-three patients received posaconazole for prophylaxis (126 posaconazole samples), and 32 of them were on MR tablets only.
A median of 2 (IQR 1-4) blood samples was taken per patient, and the median drug concentration was 1.7 mg/L (IQR 0.8-2.7), the interpatient variance was 1.53 and standard deviation 1.24. Figure 2 shows intra-and interpatient variability for patients who had 5 or more samples measured while being on the same dose. Table 3 .
The mortality rate in the total prophylaxis group was 6% (two patients) after 28 days and 24% (8 patients) after 12 weeks. 
| Longitudinal analysis
The associations of the independent variables on posaconazole concentration together with their 95% confidence interval and the Wald-type P-value are provided in Table 4 . The results on the original data (with missing data) as well as the pooled estimates from the imputation are given. The original data set contains 127 measurements (from the 182 measurements) with a complete data set.
It is obvious that the dose contributed to the posaconazole concentration. In the analysis of the original data set (with missing data), ALT seemed to contribute to the posaconazole concentration, but this association seemed to disappear when multiple imputation is being used.
Multiple imputation showed that subjects who had missing data on ALT had on average a lower ALT value that the subjects from whom we observed ALT data (34.0 vs 51.6). This may suggest that the associations of the independent variables in the original data are somewhat biased.
| D ISCUSS I ON
The objective of this study was to analyse routine TDM practices of posaconazole. Our study showed that variability in drug exposure is still present. Posaconazole concentrations might be affected by
TA B L E 2 Posaconazole concentrations during prophylaxis and treatment
(%) patients on prophylaxis
(%) patients on treatment
Route of administration Oral 32 (68) 11 (24) Intravenous and oral 1 (2) 3 (6) Loading dose 17 ( treatment setting-some patients were treated in an outpatient setting. However, some of these patients suffered from graft-vs-host disease, which can compromise the absorption of posaconazole 32 .
Variability of posaconazole C min (MR tablet) was also described in a recent study on lung transplant recipients 33 . However, we did see an increase of median posaconazole concentrations compared to a previous study done in our centre with posaconazole suspension. In that study, the median posaconazole concentration was 0.9 mg/L, and in our study, it was 1.7 mg/L (prophylaxis) and 1.76 mg/L (treatment). For most patients in van Elst et al study, the patients received mostly 600 mg/day (84%) for prophylaxis and 800 mg/day (80%) for treatment. In this study, 50% of the treatment group and 79% of the prophylaxis group received 300 mg of posaconazole per day Posaconazole concentrations have also been described to be affected by diarrhoea, body weight, male gender, use of PPIs and steroids 35, 36 . Our longitudinal analysis did not confirm the effect of weight and gender on posaconazole concentrations. We also did not see a change of AST levels, although posaconazole treatment is connected with liver function abnormalities
37
. On the other hand, it has also been presented previously that liver function markers like ƴ-GT, ALP and ALT were not connected to higher posaconazole concentrations
. A limitation of our analysis is the fact that we did not analyse the effect of diarrhoea and use of PPIs and steroids and that we included patients of a previous study, which is a part of all measured posaconazole concentrations during the study period thus does not represent the whole patient population. On the other hand, the characteristics of our data set are somewhat similar to other studies describing posaconazole exposure in patients with haematological malignancies 36, 37 . The novelty of our study compared to earlier studies is the longitudinal analysis, which is taking into account the day of treatment and the time between measurements, also including all samples that have been collected for each patient [34] [35] [36] . The advantage of using longitudinal analysis over univariate and multivariate analysis that have been used by earlier studies is that this type of analysis better values the effect of measurements over time.
We cannot see a relationship between low posaconazole concentrations and mortality rates. Additionally, this data set is too small to show that low concentrations have an effect on outcomes, especially as we did not determine IFI-attributable deaths. variables. 38 Additionally, in that study approximately for 20% of patients' dosage changes were done, which led to more therapeutic concentrations. It was suggested that there is a benefit of TDM org/0000-0001-6703-0288
| CON CLUS IONS
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